On the other hand, most clinical studies, including meta-analyses, agree that circulating irisin levels are lower in patients with T2D, obese or not [82,121,122,123,124], probably reflecting a loss of the compensatory response following greater metabolic impairment. This evidence concerns the gene FNDC5 and type 2 diabetes mellitus.